Gain Therapeutics (GANX) Accumulated Depreciation (2020 - 2026)

Gain Therapeutics has reported Accumulated Depreciation for 7 years, with the latest figure at $166061.0 in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 3.98% year-over-year to $166061.0 in Q2 2026; TTM through Jun 2026 was $166061.0, a 3.98% increase from a year earlier, with the FY2025 full-year figure at $183765.0, up 48.97% from the prior year.
• Accumulated Depreciation was $166061.0 for Q2 2026 at Gain Therapeutics, up from $153347.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $183765.0 in Q4 2025, with the low at $33045.0 in Q1 2022.
• Average Accumulated Depreciation over 5 years is $105033.1, with a median of $102148.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation surged 104.12% in 2022, then advanced 3.98% in 2026.
• Over 5 years, Accumulated Depreciation stood at $53329.0 in 2022, then soared by 74.01% to $92797.0 in 2023, then surged by 32.93% to $123357.0 in 2024, then soared by 48.97% to $183765.0 in 2025, then retreated by 9.63% to $166061.0 in 2026.
• The last three Accumulated Depreciation figures came in at $166061.0 (Q2 2026), $153347.0 (Q1 2026), and $183765.0 (Q4 2025), per Business Quant data.